Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases
Author:
Affiliation:
1. Sydney NSW Australia
2. San Diego CA USA
3. Calgary AB Canada
4. Adelaide SA Australia
5. Melbourne Vic. Australia
6. Christchurch New Zealand
7. Brisbane Qld Australia
8. Newcastle NSW Australia
Funder
Gastroenterological Society of Australia
AbbVie
Janssen
Takeda Pharmaceuticals U.S.A.
Pfizer
Publisher
Wiley
Subject
Pharmacology (medical),Gastroenterology,Hepatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14368/fullpdf
Reference185 articles.
1. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial;Colombel;Gastroenterology,2007
2. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis;Sandborn;Gastroenterology,2012
3. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis;Ford;Am J Gastroenterol,2011
4. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience;Sprakes;J Crohns Colitis,2012
5. Ustekinumab as induction and maintenance therapy for Crohn's disease;Feagan;N Engl J Med,2016
Cited by 235 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease;Frontiers in Pharmacology;2024-08-27
2. What are the benefits of therapeutic drug monitoring in the optimization of adalimumab therapy? a systematic review and meta-analysis up to 2022;Frontiers in Pharmacology;2024-07-08
3. Letter: Persisting with persistence—A caution as an outcome measure in inflammatory bowel disease: Authors' reply;Alimentary Pharmacology & Therapeutics;2024-06-24
4. Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis;Digestive Diseases and Sciences;2024-06-14
5. Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study;Gastroenterología y Hepatología (English Edition);2024-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3